Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Inozyme Pharma, a US-based mineralisation disorder drug spinout of Yale University, has filed for an $86.3m initial public offering on the Nasdaq Global Market. Founded in 2015, Inozyme is targeting on rare, debilitating diseases caused by abnormal mineralisation and affecting soft tissue, the vascular system and the skeleton. The company’s lead asset, INZ-701, aims to…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.